继发于维得利珠单抗的急性间质性肾炎。
Acute interstitial nephritis secondary to vedolizumab.
机构信息
Queen Elizabeth University Hospital, NHSGGC, Glasgow, UK
Gastroenterology, Queen Elizabeth University Hospital, Glasgow, UK.
出版信息
BMJ Case Rep. 2021 Nov 19;14(11):e243568. doi: 10.1136/bcr-2021-243568.
Abstract
We present a patient with an acute kidney injury thought secondary to acute interstitial nephritis as a result of vedolizumab maintenance therapy for Crohn's disease. This appears to be a rare but serious side effect in patients receiving this treatment which clinicians should consider in the event of renal dysfunction.
摘要
我们介绍了一位患者，其因克罗恩病而接受 vedolizumab 维持治疗，发生急性间质性肾炎导致急性肾损伤。这似乎是接受此类治疗的患者中一种罕见但严重的副作用，临床医生在出现肾功能障碍时应考虑这一情况。
相似文献
1
Acute interstitial nephritis secondary to vedolizumab.继发于维得利珠单抗的急性间质性肾炎。
BMJ Case Rep. 2021 Nov 19;14(11):e243568. doi: 10.1136/bcr-2021-243568.
2
Republished: Acute interstitial nephritis secondary to vedolizumab.再发表：维多珠单抗继发急性间质性肾炎。
Drug Ther Bull. 2023 Jun;61(6):92-95. doi: 10.1136/dtb.2022.243568.rep. Epub 2023 Jan 17.
3
Interstitial Nephritis Secondary to Vedolizumab Treatment in Crohn Disease and Safe Rechallenge Using Steroids: A Case Report.继发于克罗恩病 vedolizumab 治疗的间质性肾炎及使用类固醇安全再挑战：一例报告。
Am J Kidney Dis. 2018 Jan;71(1):142-145. doi: 10.1053/j.ajkd.2017.08.008. Epub 2017 Nov 20.
4
Vedolizumab as induction and maintenance therapy for Crohn's disease.维得利珠单抗作为克罗恩病的诱导缓解和维持治疗药物。
N Engl J Med. 2013 Aug 22;369(8):711-21. doi: 10.1056/NEJMoa1215739.
5
The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-marketing Data.维得利珠单抗在溃疡性结肠炎和克罗恩病中的安全性：全球上市后 4 年的数据。
J Crohns Colitis. 2020 Feb 10;14(2):192-204. doi: 10.1093/ecco-jcc/jjz137.
6
Acute Tubulointerstitial Nephritis Associated with Infliximab in a Patient with Crohn's Disease.一名克罗恩病患者中与英夫利昔单抗相关的急性肾小管间质性肾炎
Intern Med. 2016;55(10):1367-70. doi: 10.2169/internalmedicine.55.5834. Epub 2016 May 15.
7
Vedolizumab-induced acute interstitial nephritis with failure of steroid prophylaxis on vedolizumab rechallenge.韦多利珠单抗诱导的急性间质性肾炎，韦多利珠单抗再次使用时类固醇预防失败。
BMJ Case Rep. 2023 Sep 12;16(9):e254715. doi: 10.1136/bcr-2023-254715.
8
Infliximab-Induced Tubulointerstitial Nephritis with Image Findings of Striated Nephrogram in Crohn's Disease.英夫利昔单抗诱导的肾小管间质性肾炎伴克罗恩病中条纹状肾图的影像学表现
Tohoku J Exp Med. 2018 Jul;245(3):149-152. doi: 10.1620/tjem.245.149.
9
[Current position on Vedolizumab for ulcerative colitis and Crohn's disease].[维多珠单抗治疗溃疡性结肠炎和克罗恩病的当前立场]
Z Gastroenterol. 2015 Jun;53(6):591-602. doi: 10.1055/s-0034-1399400. Epub 2015 May 27.
10
Benefit-Risk Assessment of Vedolizumab in the Treatment of Crohn's Disease and Ulcerative Colitis.维得利珠单抗治疗克罗恩病和溃疡性结肠炎的获益-风险评估。
Drug Saf. 2019 May;42(5):617-632. doi: 10.1007/s40264-018-00783-1.
引用本文的文献
1
Insights into renal and urological complications of inflammatory bowel disease.炎症性肠病的肾脏和泌尿系统并发症的见解
World J Nephrol. 2024 Sep 25;13(3):96574. doi: 10.5527/wjn.v13.i3.96574.
2
Vedolizumab-induced acute interstitial nephritis with failure of steroid prophylaxis on vedolizumab rechallenge.韦多利珠单抗诱导的急性间质性肾炎，韦多利珠单抗再次使用时类固醇预防失败。
BMJ Case Rep. 2023 Sep 12;16(9):e254715. doi: 10.1136/bcr-2023-254715.
本文引用的文献
1
Electron microscopic findings can support multiple etiologies of nephrotoxicity in renal tubules.电子显微镜检查结果可支持肾小管肾毒性的多种病因。
Ultrastruct Pathol. 2020 Nov 20;44(4-6):481-488. doi: 10.1080/01913123.2020.1839152. Epub 2020 Nov 1.
2
British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.英国胃肠病学会成人炎症性肠病管理共识指南。
Gut. 2019 Dec;68(Suppl 3):s1-s106. doi: 10.1136/gutjnl-2019-318484. Epub 2019 Sep 27.
3
Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease.维得利珠单抗与炎症性肠病患者固有免疫而非适应性免疫的改变相关。
Gut. 2019 Jan;68(1):25-39. doi: 10.1136/gutjnl-2018-316023. Epub 2018 May 5.
4
Interstitial Nephritis Secondary to Vedolizumab Treatment in Crohn Disease and Safe Rechallenge Using Steroids: A Case Report.继发于克罗恩病 vedolizumab 治疗的间质性肾炎及使用类固醇安全再挑战：一例报告。
Am J Kidney Dis. 2018 Jan;71(1):142-145. doi: 10.1053/j.ajkd.2017.08.008. Epub 2017 Nov 20.
5
Drug-Induced Acute Interstitial Nephritis.药物性急性间质性肾炎
Clin J Am Soc Nephrol. 2017 Dec 7;12(12):2046-2049. doi: 10.2215/CJN.07630717. Epub 2017 Sep 11.
6
Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease.抗肿瘤坏死因子制剂及其他新型药物治疗炎症性肠病的研究进展。
BMJ. 2017 Jun 19;357:j2505. doi: 10.1136/bmj.j2505.
7
The safety of vedolizumab for ulcerative colitis and Crohn's disease.维多珠单抗用于溃疡性结肠炎和克罗恩病的安全性。
Gut. 2017 May;66(5):839-851. doi: 10.1136/gutjnl-2015-311079. Epub 2016 Feb 18.
8
Drug-induced acute interstitial nephritis: pathology, pathogenesis, and treatment.药物性急性间质性肾炎：病理学、发病机制及治疗
Iran J Kidney Dis. 2015 Jan;9(1):3-13.
9
The histopathologic spectrum of kidney biopsies in patients with inflammatory bowel disease.炎症性肠病患者肾活检的组织病理学谱。
Clin J Am Soc Nephrol. 2014 Feb;9(2):265-70. doi: 10.2215/CJN.04660513. Epub 2013 Nov 21.
10
Inhibition of leukocyte trafficking in inflammatory bowel disease.炎症性肠病中白细胞迁移的抑制
N Engl J Med. 2013 Aug 22;369(8):775-6. doi: 10.1056/NEJMe1307415.
Zotero 插件